Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 4/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 3/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.38 |
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29035464 | 1.00 | UCHL1 (0.46) | UCHL1MEN1KMT2ASRCABCB1 | |
| SCHEMBL29035291 | 0.88 | TACR1 (0.41) | UCHL1MEN1KMT2ATACR1NR1H2 | |
| SCHEMBL29035289 | 0.88 | TACR1 (0.41) | UCHL1MEN1KMT2ATACR1NR1H2 | |
| SCHEMBL25366989 | 0.87 | GPR119 (0.42) | UCHL1MEN1KMT2AGPR119NR1H2 | |
| SCHEMBL25366993 | 0.87 | GPR119 (0.42) | UCHL1MEN1KMT2AGPR119NR1H2 | |
| SCHEMBL30571527 | 0.86 | GPR119 (0.44) | UCHL1MEN1KMT2ASRCGPR119 | |
| SCHEMBL23632067 | 0.85 | NR1H2 (0.42) | UCHL1MEN1KMT2AGPR119TACR1 | |
| SCHEMBL23631967 | 0.85 | NR1H2 (0.42) | UCHL1MEN1KMT2AGPR119TACR1 | |
| SCHEMBL29035314 | 0.84 | MEN1 (0.43) | UCHL1MEN1KMT2ASRCABCB1 | |
| SCHEMBL29035312 | 0.84 | MEN1 (0.43) | UCHL1MEN1KMT2ASRCABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |